Market Place
Sourcing Support
Financial Results for the quarter ended 30th June 2024
09 Oct 2024 //
PRESS RELEASE
IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr
12 Aug 2024 //
PRESS RELEASE
Notice of closure of trading window
26 Jul 2024 //
PRESS RELEASE
EDQM issued CEP Certificate for “Valsartan”
12 Jul 2024 //
PRESS RELEASE
SEBI Regulation 74-5Certificate For Depository Participants: Q2 Ending June 2024
09 Jul 2024 //
PRESS RELEASE
NMPA China Approves Company`s Fenofibrate Manufacturing For Market Release
01 Jul 2024 //
PRESS RELEASE
Schedule of analyst /institutional investor meeting
15 Jun 2024 //
PRESS RELEASE
IOL Chemicals receives EDQM CEP certificate Pantoprazole Sodium Sesquihydrate
12 Jun 2024 //
PRESS RELEASE
IOL Chemicals receives EDQM CEP certificate Allopurinol
12 Jun 2024 //
PRESS RELEASE
SEBI Listing Regulations 39(3) Disclosure: Share Certificate Loss Reported
24 May 2024 //
PRESS RELEASE
Q4 And FY 2024 Audited Results: Earnings Conference Call Transcript Released
21 May 2024 //
PRESS RELEASE
IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr
15 May 2024 //
INDINPHARMAPOST
Outcome of the Board Meeting dated 14th May 2024
14 May 2024 //
PRESS RELEASE
Press Release: Financial Results for the quarter and year ended 31st March 2024
14 May 2024 //
PRESS RELEASE
GMP Certificate issued by Brazilian Health Regulatory Agency (ANVISA)
03 May 2024 //
PRESS RELEASE
CEP Certificate issued by EDQM
04 Apr 2024 //
PRESS RELEASE
Successful completion of Site Inspection by ANVISA, Brazil GMP
18 Mar 2024 //
PRESS RELEASE
CDE, China approved “Metformin Hydrochloride”
19 Feb 2024 //
PRESS RELEASE
Communication to Shareholders - Deduction of tax at source on Interim Dividend for FY 2023-24
10 Feb 2024 //
PRESS RELEASE
IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
07 Feb 2024 //
INDIAN PHARMA POST
CEP Certificate for Losartan Potassium issued by EDQM
06 Feb 2024 //
PRESS RELEASE
Outcome of the Board Meeting
06 Feb 2024 //
PRESS RELEASE
Schedule of analyst / investor conference call – Q3 & 9M FY24
05 Feb 2024 //
PRESS RELEASE
Intimation of lost share certificates
25 Jan 2024 //
PRESS RELEASE
Schedule of analyst / investor meeting
06 Dec 2023 //
PRESS RELEASE
IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
15 Nov 2023 //
INDIAN PHARMA POST
Outcome of the Board Meeting - Audited Financial Results for the quarter and half year ended 30th September 2023
08 Nov 2023 //
PRESS RELEASE
Schedule of analyst / investor conference call – Q2 & H1 FY24
06 Nov 2023 //
PRESS RELEASE
Transcript of Earnings Conference Call on audited financial results for Q1FY24
19 Aug 2023 //
PRESS RELEASE
Schedule of analyst / investor conference call – Q1FY24
14 Aug 2023 //
PRESS RELEASE
Press Release for Financial Results Q1 FY24
09 Aug 2023 //
PRESS RELEASE
CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
05 Jul 2023 //
INDIAN PHARMA POST
IOL Chemicals and Pharmaceuticals Ltd rating reaffirmed to A+ by CARE Ratings
04 Jul 2023 //
PRESS RELEASE
Commenced the Acetic Anhydride Plant
12 Jun 2023 //
PRESS RELEASE
Submission of Voting Results & Scrutinizer’s Report of Postal Ballot of IOL Chemicals and Pharmaceuticals Limited
12 May 2023 //
PRESS RELEASE
IOL gets CEP to export paracetamol to European market
08 May 2023 //
EXPRESS PHARMA
CEP Certificate for Paracetamol issued by EDQM
03 May 2023 //
PRESS RELEASE
IOL Chemicals and Pharmaceuticals appoints Vikas Vij as CEO
05 Apr 2023 //
PRESS RELEASE
IOL Chemicals and Pharmaceuticals Q3 FY23 income down 6%
09 Feb 2023 //
INDIAN PHARMA POST
Intimation of incorporation of wholly owned subsidiary
01 Feb 2023 //
PRESS RELEASE
Notice of the Board Meeting
01 Feb 2023 //
PRESS RELEASE
Intimation under Regulation 39 (3) of Securities & Exchange Board of India, 2015
20 Jan 2023 //
PRESS RELEASE
EUGMP Certification from National Institute of Pharmacy and Nutrition, Hungary
20 Jan 2023 //
PRESS RELEASE
Statement of Investor Complaints : Quarter ending 31st December 2022
11 Jan 2023 //
PRESS RELEASE
Certificate under Regulation 74(5) of SEBI (Depositories and Participants)
09 Jan 2023 //
PRESS RELEASE
Intimation of lost share certificates
04 Jan 2023 //
PRESS RELEASE
IOL Chemicals secures patent for invention related to preparation of Sartan drugs
27 Nov 2022 //
BUSINESS-STANDARD
Transcript of Earnings Conference Call organized by the Company on 15th Nov 2022
19 Nov 2022 //
PRESS RELEASE
IOL Chemicals jumps 18% in two days
16 Nov 2022 //
BUSINESS-STANDARD
IOL Chemicals board OKs setting up unit in UK
16 Nov 2022 //
BUSINESS-STANDARD
Audio Recording of Analysts/Investors Conference Call pertaining to Q2 & FY23
16 Nov 2022 //
PRESS RELEASE
Intimation under Regulation 30 of Securities and Exchange Board of India, 2015
15 Nov 2022 //
PRESS RELEASE
Schedule of analyst / investor conference call – 2Q & 1H FY23
14 Nov 2022 //
PRESS RELEASE
Press Release on Audited Financial Results for the quarter and half year ended
14 Nov 2022 //
PRESS RELEASE
Intimation under Regulation 39 (3) of Securities and Exchange Board of India
09 Nov 2022 //
PRESS RELEASE
IOL Chemicals gets EDQM certification for API supply to Europe
08 Nov 2022 //
ECONOMIC TIMES
Disclosure under Regulation 30 of SEBI (Listing Obligations & Requirements)
07 Nov 2022 //
PRESS RELEASE
